

Press Release

Abliva AB (publ), 556595-6538
08 June 2022 10:35:00 CEST - Lund,
Sweden



NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, BELARUS, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS.

Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has, in connection with the new issues announced on 31 May, 2022, and the conversion of the Company's convertible loan 2021/2022 into shares, prepared a secondary issue prospectus (the "Prospectus") which today has been approved and registered by the Swedish Financial Supervisory Authority.

Publication of Prospectus

The Prospectus has today, 8 June 2022, been approved and registered with the Swedish Financial Supervisory Authority. The Prospectus refers to both admission to trading of new shares in the Company as a result of the directed issue and conversion of the Company's convertible loan 2021/2021 to shares, that were communicated on 31 May, 2022, as well as an invitation to subscribe for shares as a result of the Rights issue published in the same press release as the directed issue on 31 May, 2022. The Prospectus, containing complete terms and conditions, instructions and application forms for the Rights issue are available on the Company's website (www.abliva.com) and on Erik Penser Bank's website (www.penser.se). The prospectus will also be available on Finansinspektionen's website (www.fi.se).

The rights issue in summary

- Shareholders in Abliva receive one (1) subscription right per share held on the record date of 8 June 2022
- Eleven (11) subscription rights entitle to subscribe for four (4) new shares
- The subscription price is SEK 0.35 per share
- Trading in subscription rights takes place during the period 10 - 21 June 2022
- The subscription period runs during the period 10 - 27 June 2022

The rights issue is 100 percent secured through underwriting commitments from external parties. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 51.3 million before issue costs. For further information on the Rights Issue, please refer to the published prospectus.

Press Release

Abliva AB (publ), 556595-6538
08 June 2022 10:35:00 CEST - Lund,
Sweden



Advisors

Erik Penser Bank AB and Van Lanschot Kempen are financial advisors to Abliva and Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the share issues. Erik Penser Bank is the acting issuing agent in connection to the share issues. Baker & McKenzie Advokatbyrå KB is legal advisor to Erik Penser Bank AB and Van Lanschot Kempen.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: <https://abliva.com/posts/news-subscription/>

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg>

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Press Release

Abliva AB (publ), 556595-6538
08 June 2022 10:35:00 CEST - Lund,
Sweden



Important information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and persons in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, Russia, Belarus, the United States or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

Attachments

[Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares](#)